Methylnaltrexone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Methylnaltrexone
- Methylnaltrexone: From Opioid-Induced Constipation to Congenital Hypotrichosis Milia
Methylnaltrexone: From Opioid-Induced Constipation to Congenital Hypotrichosis Milia
One-Sentence Summary
Methylnaltrexone is a peripherally-restricted mu-opioid receptor antagonist internationally used to treat opioid-induced constipation; no local marketing authorization or original-indication record exists in this evidence pack. The TxGNN model’s top-ranked prediction is Congenital Hypotrichosis Milia, but this pairing has no supporting clinical trials or literature (0/0), and the model’s own rationale explicitly flags it as likely knowledge-graph noise rather than a genuine mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (drug not locally marketed); internationally recognized use is opioid-induced constipation (OIC) |
| Predicted New Indication | Congenital Hypotrichosis Milia |
| TxGNN Prediction Score | 78.35% |
| Evidence Level | L5 |
| EU Market Status | Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on general drug classification knowledge, methylnaltrexone (DB06800) belongs to the peripherally-acting mu-opioid receptor antagonist (PAMORA) class, which blocks opioid effects on gastrointestinal mu-receptors without crossing the blood-brain barrier — the basis for its recognized use in opioid-induced constipation. No local (Taiwan) approved-indication text or license record is present to confirm this against the evidence pack itself.
For the top-ranked candidate, however, the evidence pack’s own repurposing rationale states there is no known pathophysiological connection between peripheral mu-opioid receptor antagonism and congenital hypotrichosis milia, a rare congenital hair/skin disorder. The rationale explicitly attributes this pairing to likely noise from rare-disease node connections within the TxGNN knowledge graph, rather than a biologically plausible mechanism.
Notably, among the 10 candidates in this evidence pack, only two show any literature-level engagement: respiratory failure (rank 7, L4) has mechanistic literature on opioid receptors and cardiorespiratory control — though the rationale itself argues methylnaltrexone’s peripheral restriction likely makes it ineffective against central respiratory depression; and alopecia/alopecia areata (ranks 5–6) have a plausible but unproven hypothesis involving mu-opioid receptor expression in hair follicle keratinocytes. Neither has any clinical trial or case-report evidence. The rank-1 candidate reported here has weaker rationale support than either of these.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No marketing authorizations are recorded for this drug in this jurisdiction (market status: Not marketed / Not marketed; total licenses: 0).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top predicted pairing (methylnaltrexone → congenital hypotrichosis milia) has zero clinical trial or literature evidence, and the model’s own mechanistic rationale identifies it as probable knowledge-graph noise rather than a credible hypothesis. Combined with a blocking data gap on TFDA warnings/contraindications (DG001) and a high-severity gap on mechanism of action (DG002), the candidate cannot proceed past initial safety screening (S0).
To proceed, the following is needed:
- TFDA label (warnings, contraindications) — required to clear Blocking gap DG001 before any S1 safety assessment
- Confirmed mechanism of action via DrugBank API — required to clear High-severity gap DG002
- Confirmation of original approved indication and local market status (currently absent from evidence pack)
- If pursuing a biologically more plausible direction, consider re-evaluating the alopecia/alopecia areata candidates (ranks 5–6), which at least have a stated (if unproven) mechanistic hypothesis — but note these also currently lack any clinical trial or literature support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.